Immunological effects of donor lymphocyte infusion in patients with chronic myelogenous leukemia relapsing after bone marrow transplantation

Brazilian Journal of Medical and Biological Research

Volumn 37, Issue 2, 2004, Pages 201-206

  Castro, F A ^a,b   Palma, P V B ^b   Morais, F R ^b   Voltarelli, J C ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Fundacao Hemocentro de Ribeirao Preto   (Brazil)

Author keywords

Bone marrow transplantation; Chronic myelogenous leukemia; Donor lymphocyte infusion; Immune system

Indexed keywords

BIOLOGICAL MARKER; CD3 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; PROTEIN BCL 2;

ADULT; APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CELL ACTIVITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; CYTOKINE PRODUCTION; DONOR; FEMALE; FLOW CYTOMETRY; HLA MATCHING; HUMAN; IN VIVO STUDY; LEUKEMIA REMISSION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFUSION; MALE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; T LYMPHOCYTE;

EID: 1442282034     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2004000200006     Document Type: Article

References (20)

1. Sawyers CL (1999). Chronic myelogenous leukemia. New England Journal of Medicine, 340: 1330-1340.
2. Clift RA & Anasetti C (1997). Allografting for chronic myeloid leukaemia. Baillieres Clinical Haematology, 10: 319-336.
3. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD & Storb E (1979). Antileukemic effects of graft versus host disease in human recipients of allogeneic marrow grafts. New England Journal of Medicine, 300: 1068-1073.
4. Kolb JH, Mittermuller J, Clemm C, Ledderooe G, Brehm G, Heim M & Wilmans W (1990). Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76: 2462-2465.
5. Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ & Goldman JM (1992). Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood, 79: 1379-1381.
6. Jiang YZ, Barrett AJ, Goldman JM & Mavroudis DA (1997). Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. Annals of Hematology, 14: 1-6.
7. Guilhot F & Lacotte-Thierry L (1998) Interferon-α: mechanisms of action in chronic myelogenous leukemia in chronic phase. Hematology and Cell Therapy, 40: 237-239.
8. Claret EJ, Alyea EP, Orsini E, Pickett CC, Collins H, Wang Y, Neuberg D, Soiffer RJ & Ritz J (1997). Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. Journal of Clinical Investigation, 100: 855-866.
9. Verfuerth S, Peggs K, Vyas P, Barnett L, O'Reilly RJ & Mackinnon S (2000) Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire. Blood, 95: 3990-3995.
10. Luznik L & Fuchs EJ (2002). Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control, 9: 123-135.
11. Boyum A (1977). Isolation of lymphocytes, granulocytes and macrophages. Scandinavian Journal of Immunology, 5 (Suppl): 9-15.
12. Chang L, Gusewitch AG, Chritton DBW, Folz JC, Lebeck LK & Cannarella SLN (1993). Rapid flow cytometric assay for the assessment of natural killer cell activity. Journal of Immunological Methods, 166: 45-52.
13. Jung T, Schauer U, Heusser C, Neumann C & Rieger C (1993). Detection of intracellular cytokines by flow cytometry. Journal of Immunological Methods, 159: 197-207.
14. Bain B, Vas MR & Lowenstein L (1964). The development of large immature mononuclear cells in mixed leukocyte cultures. Blood, 23: 108-116.
15. Deininger MWN, Goldman JM & Melo JV (2000). The molecular biology of chronic myeloid leukemia. Blood, 96: 3343-3356.
16. Ravandi F, Kantarjian HM, Talpaz M et al. (2001). Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer, 91: 1964-1972.
17. Pawelec G, da Silva P, Max H, Kalbacher H, Schmidt H, Bruserud O, Zugel U, Baier W, Rehbein A & Pohla H (1995). Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha. Leukemia and Lymphoma, 18: 471-478.
18. Murray JS (1998). How the MHC selects Th1-Th2 immunity. Immunology Today, 19: 157-162.
19. Smit WM, Rijnbeek M, van Bergen CAM, Willemze R & Falkenburg JHF (1998). Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay. Bone Marrow Transplantation, 21: 553-560.
20. Dazzi F, Szydlo RM & Goldman JM (1999). Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: Where we now stand. Experimental Hematology, 27: 1477-1486.